Background. Phospholipase A 2 receptor antibodies (PLA 2 RAb) and thrombospondin type-1 domain-containing 7A antibodies (THSD7A-Ab) are present in 70-80% of patients with membranous nephropathy (MN). Little, however, is known about the pathogenesis of MN and the clinical outcome in PLA 2 R-Ab-and THSD7A-Ab-negative patients. Methods. In this prospective multicentre observational study, the clinical outcome of 37 patients with biopsy-proven MN who were negative for PLA 2 R-Ab and THSD7A-Ab in the serum was analysed. Results. A total of 198 patients were screened for inclusion in the study. Of these, 157 patients were positive for PLA 2 R-Ab and 4 patients for THSD7A-Ab. The remaining 37 patients were negative for both antibodies were and included in this study. Six patients died during the follow-up, five because of malignant diseases and one of an infection. One patient went into end-stage renal disease, and two patients were lost to follow-up. The remaining 28 patients were followed for at least 24 months (35.6 ± 8.9 months). Seventeen patients received immunosuppressive (IS) therapy, and 11 received supportive care only. At the end of the follow-up, 14 of the 17 patients treated with immunosuppressants and 10 of 11 patients on supportive therapy had a remission of proteinuria. The time to reach remission of proteinuria and serum creatinine levels at the end of the follow-up were not different between both groups. A univariate Cox regression analysis indicated that
was not possible. Every case of MN, in which no secondary cause could be detected, was considered to be idiopathic or primary. However, the manifestation of MN and a potential secondary cause (e.g. malignant disease) in a short time frame does not prove that the malignant disease is responsible for the development of MN and may be coincidental [7] . Vice versa, even if no secondary cause of MN is detected, the possibility remains that an unknown or untested secondary cause is present. The identification of autoantibodies against the M-type phospholipase A 2 receptor (PLA 2 R) on the podocyte surface in patients with primary MN was a major step forward in the diagnosis to allow differentiation between primary and secondary MN [8] . PLA 2 R antibodies (PLA 2 R-Ab) are very specific for primary MN [9, 10] . There is increasing evidence that in patients with primary MN, PLA 2 R-Ab could serve as biomarkers of immunologic disease activity and allow making treatment decisions [11, 12] . Furthermore, thrombospondin type-1 domain-containing 7A (THSD7A) was recently identified as an additional target inducing autoimmunity in patients with primary MN, thus increasing the percentage of patients who might eventually benefit from an immunosuppressive (IS) treatment [13] .
However, there is still uncertainty whether PLA 2 R-Ab-and THSD7A-Ab-negative patients, in whom no secondary causes for MN can be detected, should be treated just like patients with primary MN and detectable PLA 2 R-Ab and THSD7A-Ab. A considerable number of patients in whom no secondary cause of MN can be detected and who are PLA 2 R-Ab negative are treated with IS agents [14] with potential serious adverse effects. Thus, the differentiation between primary and secondary MN is important for patient safety. In order to analyse the clinical outcome of PLA 2 R-Ab-and THSD7A-Ab-negative patients with MN, we performed this clinical study.
M AT E R I A L S A N D M E T H O D S
Patients and study design In this multicentre, prospective cohort study, we screened 198 consecutive patients with the histologic diagnosis of MN and proteinuria >3.5 g/24 h for PLA 2 R-Ab in their serum. Patients with a histologic diagnosis other than MN were not included in this study. The serum test for the presence of PLA 2 R-Ab had to be performed within 6 months following renal biopsy. Patients with biopsy-proven MN who were negative for PLA 2 R-Ab were included in this observational study. Since THSD7A was recently identified as another target antigen in MN, we retrospectively analysed all patients in this study for THSD7A-Ab in the serum. Four patients were tested positive for THSD7A-Ab and were excluded from further analyses. Patients were included in the study between April 2010 and December 2012. No IS therapy was allowed before inclusion in this study. Screenings for secondary causes of MN, including serologic tests for lupus erythematosus, hepatitis, detailed medical history and screening for malignancies depending on the age and risk factors of the patient were performed at the time of study inclusion or at the follow-up visits, which occurred every 3 months. Decisions on therapy were made by the treating physicians without any recommendations. The most common factors for starting IS treatments were severe clinical symptoms such as nephrotic syndrome and oedema not responding to supportive therapy or decline of renal function. When an IS treatment was chosen, the treatment protocol, as well as the dose and duration of the treatment, was documented. Proteinuria and serum creatinine were measured every 3 months. Remission of proteinuria was defined as proteinuria <3.5 g/24 h and at least 50% reduction from the time of inclusion in the study. A complete remission of proteinuria was defined as proteinuria <0.5 g/24 h; otherwise, remission was considered partial. A clinically significant increase in serum creatinine level was defined as an increase of serum creatinine by ≥25% in comparison with the serum creatinine level at study inclusion and reaching a serum creatinine level of ≥1.3 mg/dL.
The study was approved by the local ethics committee of the chamber of physicians in Hamburg and conducted in accordance with the ethical principles stated by the Declaration of Helsinki. Informed consent was obtained from all participating patients.
PLA 2 R-Ab and THSD7A-Ab measurement and staining of renal biopsies for PLA 2 R and THSD7A Serum levels of PLA 2 R-Ab were measured by an indirect immunofluorescence test [9, 10] and an enzyme-linked immunosorbent assay (ELISA) [11] as described. Both tests had to be negative. THSD7A-Ab levels were measured using a western blot technique as described [13] . PLA 2 R and THSD7A staining of renal biopsies was performed as described earlier [10, 13] .
Statistical analyses
Data are given as mean ± SD values. Statistical significance was defined as P < 0.05 (α = 0.05). The Kaplan-Meier method was employed for survival analysis on the end point remission of proteinuria by computing cumulative hazard curves for patients receiving immunosuppressants or supportive treatment only. The curves were compared via a log-rank test. Univariate Cox regression analysis was performed on the end point remission of proteinuria, employing clinical variables measured at the beginning of the study (age, sex, proteinuria, serum creatinine, time between renal biopsy and measurement of PLA 2 R-Ab levels), as well as follow-up time and the use of IS treatment during the follow-up. These explanatory variables were chosen because of their potential influence on the development of proteinuria.
For all variables, the proportional hazard assumption was tested and found to be fulfilled. Survival analyses and Cox regressions were done using Stata version 13. All other statistical analyses were done using SPSS version 21.
R E S U LT S
Clinical baseline characteristics The serum of 198 consecutive patients with biopsy-proven MN was screened for the presence of PLA 2 R-Ab and THSD7A-Ab (Figure 1 ). The serum test for the presence of PLA 2 R-Ab and inclusion in the study was performed 2.6 ± 3.8 weeks after renal biopsy and diagnosis of MN. Of the 198 patients, 157 patients were positive for PLA 2 R-Ab and 4 patients were positive for THSD7A-Ab. The remaining 37 patients were negative for both antibodies and were included in this study. Twenty-four patients were male, and the mean age of the patients was 57.6 ± 15.9 years. At the time of inclusion in this study, most patients (33 out of 37, 90%) were treated with an angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker. Diuretics were used in 22 (57%) patients, lipid-lowering drugs in 24 (65%) and anticoagulants in 15 (41%) patients at study start. There were no statistically significant differences in the clinical characteristics between PLA 2-R-Ab-positive and PLA 2 R-Ab-negative patients at study inclusion (Table 1) .
Clinical follow-up
For 28 of the 37 patients, a clinical follow-up of at least 24 months was completed. In five of the remaining nine patients, a malignant disease was diagnosed, which allowed no further follow-up because the patients died, or their primary disease further advanced and their treatment was palliative. Four patients did not complete the follow-up. One patient died because of an infection 25 months after inclusion in the study. This patient had a remission of proteinuria under immunosuppression with cyclosporine A, which was terminated 1 year before the patient died. One patient had an impaired renal function prior to renal biopsy and needed dialysis within 1 month after renal biopsy. Therefore, he was excluded from further analyses. Two patients discontinued the study visits and were lost to follow-up.
Clinical outcome
We analysed the clinical outcome of the 28 patients who completed a follow-up of at least 24 months (Table 2 ). Immunosuppression was applied in 17 of these 28 patients. The remaining 11 (40%) patients were treated with supportive therapy only. Patients treated with immunosuppressants had similar clinical characteristics at the start of the study when compared with patients on supportive treatment (Table 3) . Ten (91%) out of the 11 PLA 2 R-Ab-negative patients treated with supportive care had a spontaneous remission of proteinuria, and 7 of them went into complete remission. In the group of 17 patients who were treated with immunosuppressants, 14 (82%) had a remission of proteinuria and 9 of those were complete remissions. Remission of proteinuria was reached earlier (8.1 ± 4.7 months versus 9.9 ± 10.0 months) in patients treated with supportive therapy, compared with At the start of the study, there were no statistically significant differences in any of the baseline clinical characteristics between PLA 2 R-Ab-positive and PLA 2 R-Ab-negative patients.
F I G U R E 1 :
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patients treated with immunosuppressants. This difference was not statistically significant (P = 0.62) (Figure 2 ). Of the 157 PLA 2 R-Ab-positive patients, only 28 (18%) received no IS therapy and 18 (64%) of them had a spontaneous remission of proteinuria. Two patients treated with immunosuppressants and one patient treated with supportive care only had a significant increase in serum creatinine level defined as serum creatinine ≥1.3 mg/ dL and an increase of ≥25% compared with the serum creatinine levels at study start. The serum creatinine levels were not significantly different between patients treated with or without immunosuppressants at the end of the follow-up (1.2 ± 0.5 mg/dL versus 1.2 ± 0.6 mg/dL, P = 0.96).
We performed a univariate Cox regression analysis to identify risk factors associated with remission of proteinuria in our patient cohort. We included the variables age, sex, proteinuria at the start of the study, serum creatinine at the start of the study, time between renal biopsy and measurement of PLA 2 R-Ab levels, the use of IS treatment and the follow-up time in theses analyses. The hazard ratios and their confidence intervals indicate that on average and adjusting for the effects of all other variables in the analyses, none of the tested variables, especially the use of immunosuppression, alter the likelihood for remission of proteinuria in the univariate analysis ( Figure 3 ).
PLA 2 R staining of renal biopsies
We were able to perform a PLA 2 R staining in renal biopsies in 18 of the 28 patients who completed the study follow-up. Three of these biopsies showed enhanced staining for PLA 2 R. All three patients had a remission of proteinuria, one of them received immunosuppressants and two of the three patients had a spontaneous remission of proteinuria. The remaining 15 patients had no enhanced PLA 2 R staining. Nine of the 15 patients were treated with immunosuppressants (6 of them had a remission of proteinuria) and 6 with supportive care only (5 of them had a remission of proteinuria). In patients with an enhanced staining for PLA 2 R in the renal biopsy, the hazard ratio for having a remission of proteinuria was 2.44-fold higher (95% confidence interval 0.66-9.02; P = 0.182) compared with patients with no enhanced staining for PLA 2 R in the renal biopsy. A THSD7A staining could be performed in 17 renal biopsies, but none of them showed enhanced THSD7A staining.
Immunosuppressive therapy
Immunosuppression was used in 17 (61%) of the 28 patients who were followed for at least 24 months. Calcineurin inhibitors were used in 12 patients (10 of them in combination with glucocorticoids), alkylating agents plus glucocorticoids in 6 patients and rituximab in 3 patients (1 of them in combination with glucocorticoids). Azathioprine and mycophenolate mofetil were used in combination with glucocorticoids in one patient, and two patients received glucocorticoids only. In six patients, immunosuppression was switched from one agent to another. There were no statistically significant differences in any of the baseline clinical characteristics between patients who received IS treatment during the study follow-up and those who received supportive treatment only, neither at the start of the study nor at the time when immunosuppression was started. P-values are given for the comparison of clinical characteristics at study inclusion between patients who received IS treatment and those who received supportive treatment only. Patients with a secondary cause of MN In 9 of the 37 patients in the study, a possible secondary cause or disease associated with MN was diagnosed. Five of these patients had a malignant disease, which progressed. One patient had a non-Hodgkin's lymphoma, and one patient had a lung carcinoma. The diagnoses were made at the time of inclusion in the study. In two patients, a lung carcinoma was diagnosed within 3 and 7 months after inclusion in this study, and one malignant lymphoma was diagnosed within 1 month of inclusion in this study.
The remaining four patients could be followed for at least 24 months, and all had a remission of proteinuria. One patient had an exposure to nonsteroidal anti-inflammatory drugs (NSAID) 6 months prior to manifestation of MN; however, he was treated with cyclophosphamide since discontinuation of NSAID treatment did not lead to remission of proteinuria. One patient had a chronic inflammatory disease of the central nervous system requiring IgG treatment 3 months prior to manifestation of MN. The patient received glucocorticoids because of the inflammatory disease. One patient had a monoclonal gammopathy of undetermined significance diagnosed at the time of inclusion in the study, showing no progress during the study follow-up. This patient did not receive immunosuppression. One patient had a colon carcinoma diagnosed at the time of inclusion in the study, which could be removed and there were no signs of relapse during the study follow-up. This patient also did not receive immunosuppressants.
D I S C U S S I O N
Primary MN is an autoimmune disease, and the use of immunosuppressants has been shown to be beneficial in its treatment [15] [16] [17] . On the other hand, considering the substantial F I G U R E 3 : Univariate Cox regression analysis of all patients completing 24 months follow-up. The explanatory variables serum creatinine, proteinuria and time between renal biopsy and measurement of PLA 2 R-Ab levels were ln-transformed prior to analysis. The effects of none of the parameters are significant at α = 0.05. *The hazard ratios for serum creatinine, proteinuria and time between renal biopsy and measurement of PLA 2 R-Ab levels show the increase of risk per unit increase in the natural logarithm of the variable. **The hazard ratios for age show the increase of risk per unit increase of the variable.
§ The variables sex and immunosuppression are dichotomous. The hazard ratios show the risk in men compared with women and in patients who received immunosuppressants compared with those who did not.
Survival analysis by treatment. The time to reach the study end point, defined as remission of proteinuria, was not statistically different between patients treated with immunosuppressants and with supportive treatment only. The cumulative rate of patients who reached remission of proteinuria during the follow-up was also not statistically different between the two groups. N = number of patients.
percentage of patients with MN achieving spontaneous remission and the potentially severe toxicity of IS therapy, a restrictive use of immunosuppression seems to be more adequate in many patients [18] . The finding that the PLA 2 R is a major antigen in primary MN [8] allows determining the disease activity, making a differential diagnosis and guiding treatment in these patients [11] . In patients negative for PLA 2 R-Ab, however, the problem concerning the decision on IS therapy remains. Some of these patients have a secondary cause of MN, and their treatment is directed against the underlying disease. However, often the cause or a relationship of MN with another disease cannot be found [7] . The appearance of MN and the potential secondary cause may also be coincidental.
In most PLA 2 R-Ab-negative patients, no secondary cause of disease can be found. These patients might have a yet unknown secondary cause of MN or an immunologically non-active disease, and it has recently been demonstrated that proteinuria may persist for some time after PLA 2 R-Ab levels become undetectable [11, 19] . In both situations, patients would not benefit from IS therapy.
Another possibility is that MN in these patients might be initiated by an interaction of antibodies with antigens different from PLA 2 R [13] . This has now been shown for THSD7A, which plays a role in the development of MN in some of the PLA 2 R-Ab-negative patients and might eventually serve as a biomarker for disease activity in these patients [13] . Since the objective of this study was to analyse antibody-negative patients with MN, we excluded the four THSD7A-Ab-positive patients from the study.
While in PLA 2 R-Ab-and THSD7A-Ab-positive patients, antibody levels may guide therapy [11] [12] [13] 19] , there are no markers for the efficiency of a therapy in antibody-negative patients, and the possibilities to predict their clinical outcome are vague.
In 24% of the patients in our cohort, a potential secondary cause of disease could be identified. Most importantly, in five of these patients, the underlying disease determined the prognosis. This underscores the need to search for a secondary cause in patients with MN who are negative for PLA 2 R-Ab. In some cases, it could be reasonable to repeat or expand the screening for malignancies, i.e. in older patients who show a persistence of proteinuria during the follow-up. While it is not possible to provide ultimate proof of the causality between the secondary cause and development of MN in all of these cases, the clinical course of the disease in some of these patients favours the concept that MN was of secondary origin. At the same time, the patient with use of NSAID months before the diagnosis of MN was made is an example of the difficulties in the differential diagnosis between primary and secondary MN. The patient's history and the negativity of PLA 2 R-Ab and THSD7A-Ab suggest a secondary form of MN. However, upon cessation of NSAID, proteinuria persisted. Three months after start of IS treatment, the patient went into remission. This might suggest the presence of an unknown antibody-antigen pair, other than PLA 2 R and THSD7A, in this patient. In our view, such cases should not be definitively categorized as secondary MN and more emphasis should be placed on the search of further antigens, responsible for the development of MN.
Seventeen of the 28 patients who completed the study follow-up were treated with immunosuppressants. Our data do not allow a comparison between the different IS therapies since the decision to treat patients with an immunosuppressant or with supportive medication was made by the physicians based only on their individual clinical judgement. This is important, since it reflects the clinical reality for these patients, when no reliable markers of prognosis and outcome exist. Although our study was not randomized, the clinical baseline characteristics at study inclusion and at the time when immunosuppression was started did not differ between patients who later received immunosuppressants and those who remained on supportive care. Thus, the risk for a poor outcome in these patient cohorts could not be predicted by their clinical characteristics. Ten of the 11 patients on supportive treatment had a remission of proteinuria, which occurred slightly faster than in patients treated with immunosuppressants. In the univariate analysis, use of immunosuppression was not associated with a better outcome in this patient cohort. The number of patients having complete or partial remissions of proteinuria was also not significantly different between patients treated with or without immunosuppressants. Hence, we could not detect any benefit from the use of immunosuppression in this patient cohort. As reported earlier, some PLA 2 R-Ab-positive patients in this cohort had a spontaneous remission of proteinuria [11] . The percentage of PLA 2 R-Ab-negative patients with spontaneous remission of proteinuria seems to be somewhat higher than in PLA 2 R-Ab-positive patients; however, since treatment decision was not made per-protocol, the study was not randomized and the sample size is small, no definitive conclusions can be made. The small sample size of our study might also lead to differences in outcome between the groups not being detected as statistically significant.
In this study, decisions on when to start a treatment and the choice of IS therapy were made by the caring physicians and not per-protocol. Therefore, our data do not allow a comparison of the different IS therapies and their role on outcome. This fact might represent a bias in our study, although clinical characteristics of patients treated with immunosuppressants at the time of study inclusion and at start of immunosuppression were not statistically different from patients treated with supportive medication only. In 8 of the 11 patients treated with supportive therapy, a PLA 2 R staining of the renal biopsy could be performed. Two of these biopsy specimens showed an enhanced PLA 2 R staining, while blood results were PLA 2 R-Ab negative, suggesting that these patients were already in immunologic remission of disease, while proteinuria persisted. Of the remaining six patients with non-enhanced PLA 2 R or THSD7A staining, five had a spontaneous remission of proteinuria. In these patients, another yet undetected secondary cause of MN or an antibodyantigen pair other than PLA 2 R or THSD7A might be the cause for the development of MN. In both cases, however, the cause (or antibodies) spontaneously disappeared and patients had a remission of proteinuria.
We also cannot rule out the possibility that in some of the patients treated with IS therapy, an antibody-antigen pair other than PLA 2 R or THSD7A might have played a role and the treatment leads to remission of MN. Yet, the fact that all, except one patient on supportive care, had a remission of proteinuria suggests that patients with antibodies other than PLA 2 R or THSD7A were either in the supportive care group and had spontaneous remission (in this case, they would have needed no immunosuppression), or they were in the IS-treated group (in this case, their number should be rather small). Without knowledge about possible antibodies or their antigens involved, a definitive answer to this question remains elusive.
In summary, our data show that PLA 2 R-Ab-and THSD7A-Ab-negative patients with MN have a high rate of spontaneous remission of proteinuria and a more conservative approach in the use of immunosuppressants might be recommendable for these patients.
